ADXN
Addex Therapeutics Ltd
There isn't enough reported data to score ADXN yet.
UNH
UnitedHealth Group Incorporated
UNH's fundamentals are mixed: free cash flow grew 31%, but earnings per share fell 8.5%. At 23x earnings, it's trading right at its usual valuation. Analysts expect strong earnings growth, though they disagree widely on how much.
ADXN Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Weak | |
| Weak | |
| Unavailable |
ADXN's revenue, profitability and cash flow are currently weak. There isn't enough data to rate its balance sheet.
UNH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Healthy |
UNH's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
ADXN PE Valuation
ADXN has no meaningful PE right now: it lost money over the past year.
UNH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 18x | $405 | — |
| Cheap | 19x | $325 | -20% |
| Fair | 23x | $410 | +1.2% |
| Current | 23x | $405 | — |
| Expensive | 30x | $526 | +30% |
Historical ranges are pointers, not guarantees.
UNH's PE is in its fair range at 23x. If earnings grow as analysts expect, today's price would be 18x next year's earnings, in its cheap range.
ADXN Forward outlook
There aren't enough analyst estimates for ADXN to show an outlook.
UNH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Improving | |
| Moderate | |
| Low |
Analysts expect UNH's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
ADXN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$6.75 | +$2.35 |
| Q1 2026 | -$8.20 | -165% |
| Q4 2025 | -$8.92 | -188% |
| Q3 2025 | -$8.85 | -216% |
| Q2 2025 | -$9.10 | -283% |
| Q1 2025 | $12.57 | +$31.74 |
| Q4 2024 | $10.16 | +$30.43 |
| Q3 2024 | $7.61 | +$32.39 |
ADXN is still losing money, but far less than before: $6.75 per share over the past year, against $88.12 at its worst in early 2020.
UNH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $22.65 | +29% |
| Q3 2026 | $17.55 | -8.5% |
| Q2 2026 | $15.58 | -33% |
| Q1 2026 | $13.28 | -44% |
| Q4 2025 | $13.23 | -15% |
| Q3 2025 | $19.17 | +25% |
| Q2 2025 | $23.09 | +53% |
| Q1 2025 | $23.89 | +46% |
| Q4 2024 | $15.51 | -35% |
UNH has the edge over ADXN on earnings quality, reporting a profit while its opponent remains loss making.
ADXN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.9K | -73% |
| Q4 2025 | $299 | -84% |
| Q3 2025 | $35.8K | -45% |
| Q2 2025 | $43.8K | -68% |
| Q4 2024 | $1.8K | -99% |
| Q3 2024 | $64.8K | -84% |
| Q2 2024 | $138.8K | -82% |
| Q1 2024 | $281.1K | -53% |
ADXN's revenue has slid since its 2020 peak: $11,928 last quarter, down 73% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -6484% | -4470 points |
| Q1 2026 | -6239% | N/A |
| Q4 2025 | -314219% | -284668 points |
| Q3 2025 | -2342% | -1186 points |
| Q2 2025 | -2015% | -1235 points |
| Q4 2024 | -29551% | -27803 points |
| Q3 2024 | -1156% | -927 points |
| Q2 2024 | -780% | -717 points |
ADXN's operating margin was −6484% last quarter, down 4470 points from the same quarter a year ago.
UNH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $112.7B | -0.4% |
| Q2 2026 | $112B | +0.4% |
| Q1 2026 | $111.7B | +2% |
| Q4 2025 | $113.2B | +12% |
| Q3 2025 | $113.2B | +12% |
| Q2 2025 | $111.6B | +13% |
| Q1 2025 | $109.6B | +9.8% |
| Q4 2024 | $100.8B | +6.8% |
UNH has the edge over ADXN on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.8% | +2 points |
| Q2 2026 | 7.1% | +2.5 points |
| Q1 2026 | 8.1% | -0.3 points |
| Q4 2025 | 0.3% | -7.4 points |
| Q3 2025 | 3.8% | -4.8 points |
| Q2 2025 | 4.6% | -3.4 points |
| Q1 2025 | 8.3% | +0.4 points |
| Q4 2024 | 7.7% | -0.4 points |
UNH has the edge over ADXN on profitability, with a higher operating margin.
ADXN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$564.2K | -$58.8K |
| Q1 2026 | -$922K | -$201.2K |
| Q4 2025 | -$732.4K | -$704.1K |
| Q3 2025 | -$641.9K | -$160.5K |
| Q2 2025 | -$505.4K | +$2.8M |
| Q1 2025 | -$720.8K | +$1.9M |
| Q4 2024 | -$28.4K | +$723.1K |
| Q3 2024 | -$481.4K | +$2.2M |
ADXN has burned cash in almost every quarter: −$3M over the past year, against −$2M the year before.
UNH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.3B | -16% |
| Q2 2026 | $10.3B | +63% |
| Q1 2026 | $8.1B | +79% |
| Q4 2025 | $160M | -89% |
| Q3 2025 | $5.1B | -61% |
| Q2 2025 | $6.3B | +6.9% |
| Q1 2025 | $4.6B | +1037% |
| Q4 2024 | $1.5B | +$7.6B |
UNH has the edge over ADXN on cash generation, producing positive trailing cash flow while its opponent burns cash.
ADXN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.9% | +27K shares |
| 1 year | +90% | +687K shares |
| 3 years | +142% | +852K shares |
| 5 years | +412% | +1.2M shares |
| Available history | +559% | +1.2M shares |
ADXN has 1M diluted shares, up 90% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | $1,516 |
| Q1 2026 | $3,829 |
| Q4 2025 | — |
| Q3 2025 | $3,306 |
| Q2 2025 | $31,176 |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
ADXN spent $8,651 buying back its own shares over the past year, down 72% from the year before.
UNH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -4M shares |
| 1 year | -0.7% | -6M shares |
| 3 years | -3.6% | -34M shares |
| 5 years | -5.5% | -53M shares |
| Available history | -6.6% | -64M shares |
UNH has the edge over ADXN on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $3.4B |
| Q2 2026 | $1.6B |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $2.5B |
| Q1 2025 | $3B |
| Q4 2024 | $5B |
UNH spent $5B buying back its own shares over the past year, down 52% from the year before.
ADXN Net Leverage
ADXN's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
UNH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.7x | Healthy |
| Q2 2026 | 1.7x | Healthy |
| Q1 2026 | 2.2x | Moderate |
| Q4 2025 | 2.3x | Moderate |
| Q3 2025 | 1.7x | Healthy |
| Q2 2025 | 1.5x | Healthy |
| Q1 2025 | 1.3x | Healthy |
| Q4 2024 | 1.4x | Healthy |
UNH's net debt is about 1.7 years of its operating earnings (EBITDA), about the same as a year ago.
ADXN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 54.8 | Neutral |
| Stochastic | 31.0 | Neutral |
ADXN's weekly RSI is 55 (neutral) and its Stochastic is 31 (neutral).
UNH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.4 | Neutral |
| Stochastic | 60.0 | Neutral |
UNH's weekly RSI is 56 (neutral) and its Stochastic is 60 (neutral).
ADXN PE vs Healthcare Sector
| Metric | ADXN | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
ADXN has no meaningful PE right now: it lost money over the past year.
UNH PE vs Healthcare Sector
| Metric | UNH | Sector median | Relative |
|---|---|---|---|
| PE | 23x | 26x | 11% below |
| PE % | 47 | 29 | 18 pts above |
UNH is trading at 23x earnings, a 11% discount to the Healthcare sector's median of 26x.
ADXN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.37 | 57% above |
| 20 week MA | $4.35 | 22% above |
| 50 week MA | $5.99 | 12% below |
| 100 week MA | $7.17 | 26% below |
| 200 week MA | $9.61 | 45% below |
ADXN has bounced recently, but its long-term trend is still down: it's above its 8- and 20-week averages, but 45% below its 200-week average.
UNH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $394.2 | 2.8% above |
| 20 week MA | $400.5 | 1.2% above |
| 50 week MA | $361.2 | 12% above |
| 100 week MA | $376.0 | 7.8% above |
| 200 week MA | $446.6 | 9.3% below |
UNH has the edge over ADXN on trend strength, trading above more of its moving averages.
ADXN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $226.0 | $483.8 | +114% |
| 2021 | $483.8 | $132.6 | -73% |
| 2022 | $132.6 | $11.2 | -92% |
| 2023 | $11.2 | $6.05 | -46% |
| 2024 | $6.05 | $7.52 | +24% |
| 2025 | $7.52 | $7.99 | +6.3% |
| 2026 YTD | $7.99 | $5.29 | -34% |
ADXN's yearly returns have swung widely, from +114% in 2020 to −92% in 2022. It's down 34% so far in 2026.
UNH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $296.0 | $340.8 | +15% |
| 2021 | $340.8 | $495.4 | +45% |
| 2022 | $495.4 | $531.3 | +7.3% |
| 2023 | $531.3 | $526.5 | -0.9% |
| 2024 | $526.5 | $510.0 | -3.1% |
| 2025 | $510.0 | $331.8 | -35% |
| 2026 YTD | $331.8 | $405.1 | +22% |
UNH has the edge over ADXN on returns for 2026, with the stronger performance.